Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECETEP: PSMA PET for monitoring prostate cancer after focal HIFU
2026-525181-22-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary: PSMA PET detection of prostate cancer recurrence at 1 year. Planned start Jun 2026; status: authorised.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2026-525181-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525181-22-00.